Adenosine A_{2A} receptor activation decreases reperfusion injury associated with high-flow reperfusion

Steven M. Fiser, MD
Curtis G. Tribble, MD
Aditya K. Kaza, MD
Stewart M. Long, MD
John A. Kern, MD
David C. Cassada, MD
Joel Linden, PhD
Jayson Rieger, BS
Victor E. Laubach, PhD
Andy Matisoff, BS
Irving L. Kron, MD

From the Department of Thoracic and Cardiovascular Surgery, University of Virginia Health Sciences Center, Charlottesville, Va.

Supported by the National Institutes of Health (NIH) under R01 grant HL56093-03, National Research Service Award F32 grant HL10248-01, and cooperative agreement U54 HD28934 as part of the Specialized Cooperative Centers Program in Reproduction Research.

Read at the Eighty-first Annual Meeting of The American Association for Thoracic Surgery, San Diego, Calif, May 6-9, 2001.

Received for publication May 15, 2001; revisions requested June 28, 2001; revisions received Dec 27, 2001; revisions requested Feb 13, 2002; revisions received Feb 18, 2002; accepted for publication Feb 21, 2002.

Address for reprints: Steven M. Fiser, MD, Department of Thoracic and Cardiovascular Surgery, University of Virginia Health Sciences Center, PO Box 801359, MR4 Building, Room 3111, Charlottesville, VA 22908 (E-mail: smf9e@virginia.edu).

J Thorac Cardiovasc Surg 2002;124:973-8

Copyright © 2002 by The American Association for Thoracic Surgery

0022-5223/2002 \$35.00+0 12/6/124886

doi:10.1067/mtc.2002.124886

Introduction: High pulmonary artery flow rates can result in severe reperfusion injury after lung transplantation. Our hypothesis was that selective activation of the adenosine A_{2A} receptor with a highly specific analog (ATL-146e) would inhibit leukocyte activation and decrease reperfusion injury after high-flow reperfusion.

Methods: Using our isolated, ventilated, blood-perfused rabbit lung model, all groups (n = 8 per group) underwent lung harvest, 4 hours of cold storage, and blood reperfusion for 30 minutes. Measurements of pulmonary artery pressure (in millimeters of mercury), arterial oxygenation (in millimeters of mercury), myeloperoxidase, peak inspiratory pressure, and wet/dry weight ratio were obtained. Groups 1 (high flow) and 2 (high flow ATL-146e) underwent reperfusion at 120 mL/min for 30 minutes. Groups 3 (controlled high flow) and 4 (controlled high flow ATL-146e) underwent controlled reperfusion with an initial reperfusion of 60 mL/min for the first 5 minutes, followed by a rate of 120 mL/min for 25 minutes. During reperfusion, groups 2 and 4 received ATL-146e at $4 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$.

Results: ATL-146e significantly improved lung physiologic measurements under both high-flow (group 1 vs group 2) and controlled high-flow (group 3 vs group 4) conditions after 30 minutes.

Conclusions: The adenosine A_{2A} receptor analogue ATL-146e significantly decreases the severity of reperfusion injury in the setting of both high-flow and controlled high-flow reperfusion.

Despite improvements in lung transplantation, transplanted lungs remain vulnerable to ischemia-reperfusion injury, with severe graft dysfunction occurring in 20% of lung transplant recipients.^{1,2} Although severe graft dysfunction can be reversible, it is often associated with the need for prolonged intensive care and increased mortality.^{3,4} It has become increasingly evident that reperfusion is responsible for the majority of tissue injury after lung transplanta-

Figure 1. Isolated, blood-perfused rabbit lung model: diagram of the isolated lung model. P, Pressure transducer; N2, nitrogen gas; O2, oxygen gas.

tion.⁵ Additionally, some investigators have suggested that high pulmonary artery flow rates increase the risk of severe reperfusion injury after lung transplantation. In our clinical practice, patients with preexisting pulmonary hypertension are at increased risk for reperfusion injury.⁶ Other authors have also shown that a more severe reperfusion injury seems to occur in these patients as well.⁷⁻⁹ The increased risk for reperfusion injury in these patients might be the result of activation of the inflammatory cascade against endothelium that is damaged as a result of the high-flow state. Our hypothesis was that selective activation of the adenosine A_{2A} receptor with a highly specific analogue (ATL-146e) would inhibit leukocyte activation and decrease reperfusion injury after high-flow reperfusion.

Materials and Methods

Experimental Protocol

Using our isolated, ventilated, blood-perfused rabbit lung model, all groups (n = 8 per group) underwent lung harvest, 4 hours of cold storage, and blood reperfusion for 30 minutes. Groups 1 (high flow) and 2 (high flow ATL) underwent reperfusion at 120 mL/min for 30 minutes. Groups 3 (controlled high flow) and 4 (controlled high flow ATL) underwent controlled reperfusion with an initial reperfusion rate of 60 mL/min for the first 5 minutes, followed by a rate of 120 mL/min for 25 minutes. During reperfusion, groups 2 and 4 received ATL-146e at $4 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$. This dose was selected after a preliminary experiment with doses of ATL-146e at 0.01, 0.1, 1.0, and $4.0 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$.

Harvest Procedure

Adult New Zealand White rabbits of both sexes weighing 3.0 to 3.5 kg were randomly assigned to the 3 experimental groups. Animals were anesthetized with intramuscular ketamine (50 mg/kg) and xylazine (5 mg/kg). Tracheal intubation was performed

through a tracheostomy, and mechanical ventilation was instituted with a constant pressure ventilator (#RSP1002; Kent Scientific Corp, Litchfield, Conn) with room air at a rate of 18 breaths/min. A median sternotomy and thymectomy were then performed. The 2 superior and 1 inferior venae cavae were loosely encircled with ligatures, and the pericardium was opened. Both the pulmonary artery (PA) and aorta were dissected free and similarly encircled. A purse-string suture was placed in the free wall of the right ventricle, and intravenous heparin was administered (500 U/kg). After injection of $30 \mu\text{g}$ of alprostadil (prostaglandin E₁; Upjohn Company, Kalamazoo, Mich) into the PA, the cavae were interrupted, and onset of ischemia was noted. The PA was then cannulated through a right ventriculotomy placed in the center of the purse-string suture. Both the right ventricle and PA ligatures were tied to secure the cannula. After venting the left ventricle with a left ventriculotomy and ligating the aorta, 50 mL/kg Euro-Collins (Hamburg, Germany) preservation solution was infused at 4°C into the PA from a height of 30 cm. Topical cooling was achieved with cold saline solution slush. During the PA flush, the left atrium was cannulated through the left ventriculotomy with an outflow catheter and a catheter to directly transduce left atrial pressures. A purse-string suture was placed to secure these cannulas. After completion of the PA flush, the inflow and outflow cannulas were clamped. The heart-lung block was then excised, and the tracheostomy tube was clamped at end inspiration. The inflated lungs were stored immersed in saline solution at 4°C for 4 hours. All animals received humane care in compliance with the "Guide for the Care and Use of Laboratory Animals," published by the National Institutes of Health (National Institutes of Health publication No. 85-23, revised 1996).

Reperfusion Procedure

After organ harvest and ischemic storage, the heart-lung block was suspended in a warm, humidified tissue chamber, and ventilation was reestablished with a 95% oxygen and 5% carbon dioxide gas

Figure 2. Arterial oxygenation. The high-flow ATL group (*High-ATL*) had significantly improved arterial oxygenation after 30 minutes of reperfusion compared with that of the high-flow (*High*) group. Similarly, the controlled high-flow ATL (*CP-ATL*) group had significantly improved arterial oxygenation compared with that of the controlled high-flow (*CP*) group. * $P = .002$, high-flow ATL group versus high-flow group; ** $P = .004$, controlled high-flow group ATL versus controlled high-flow group.

mixture at a respiratory rate of 18 breaths/min by using the constant pressure ventilator (Figure 1). The inflow and outflow cannulas were then connected to a venous blood reperfusion circuit. New Zealand White rabbits weighing 3.5 to 5.0 kg served as fresh venous blood donors. The lungs were reperfused with venous blood from a main reservoir. A second nonrecirculated venous blood reservoir was used to challenge the lungs and to determine the single-pass oxygenation values during reperfusion. The circuit (Kent Scientific Corp) was designed to recirculate 150 mL of warmed blood with a roller pump (#7521-40; Cole Palmer Instrument Co, Chicago, Ill).

Continuous recordings of pulmonary artery pressure (PAP), left atrial pressure, and air flow were performed with a dynamic data-acquisition program (Workbench PC; Strawberry Tree, Inc, Sunnydale, Calif) on a personal computer (#470A; Compaq Prolinea, Houston, Tex). This program automatically calculated and displayed tidal volume, pulmonary vascular resistance, and dynamic airway compliance. Pulmonary venous blood samples were collected for blood gas analysis (Corning 178pH/Blood Gas Analyzer; Corning Inc, Corning, NY) after 10, 20, and 30 minutes of reperfusion. At each sampling interval, inflow from the main reservoir was temporarily interrupted, and the circuit was filled with nonrecirculated blood from the second inflow reservoir. A 30-mL sample of venous blood was passed through the pulmonary vasculature at each interval to obtain accurate measurements of pulmonary venous oxygen content. Oxygen contact with exposed blood surfaces was minimized by means of continuous passive infusion of 100% nitrogen.

Lung Wet/Dry Weight Ratios

Lung wet/dry weight ratios were used as a measurement of pulmonary edema. Samples of lung tissue were weighed immediately after reperfusion. These samples then underwent passive desiccation at room temperature until a stable dry weight was achieved. The weight immediately after reperfusion and the stable dry weight were then used to calculate the lung wet/dry weight ratios.

Lung Tissue Myeloperoxidase

A myeloperoxidase assay was performed to quantify neutrophil sequestration. Lung tissue was placed in 5 mL of 0.5% hexadecyltrimethyl-ammonium bromide in 50 mmol/L potassium phosphate solution (pH 7.4) and disrupted by means of homogenizing at 4°C. The solution was centrifuged at 15,000g for 15 minutes at 4°C, and the supernatant was discarded. The pellet was resuspended in 2 mL of 0.5% hexadecyltrimethyl-ammonium bromide in 50 mmol/L potassium phosphate solution (pH 6.0) and homogenized. Tissue was disrupted further by means of ultrasonication and 3 freeze-thaw cycles (liquid nitrogen bath/37°C water bath). The solution was again centrifuged at 15,000g for 15 minutes at 4°C. Aliquots (0.1 mL) of supernatant were added to the assay buffer of *o*-dianisidine dihydrochloride, H₂O₂, and 50 mmol/L potassium phosphate (pH 6.0). Absorbance at 460 nm was measured over 2 minutes by means of spectrophotometry (LKB Model 4050, Cambridge, England). Lung tissue myeloperoxidase activity was expressed as the change in absorbance per milligram of dry weight per minute.

Figure 3. Pulmonary artery pressure. The high-flow ATL group (*High-ATL*) had a significantly lower PAP compared with that of the high-flow (*High*) group. Similarly, the controlled high-flow ATL (*CP-ATL*) group had significantly improved PAP measurements compared with those of the controlled high-flow (*CP*) group. * $P < .015$, high-flow ATL group versus high-flow group; ** $P < .003$, controlled high-flow ATL group versus controlled high-flow group.

Statistical Analysis

Statistical analysis was performed by using analysis of variance on SPSS software (SPSS Inc, Chicago, Ill). Significant differences were determined by using the Tukey significant difference test. Data are expressed as means $\pm$ SD.

Results

Physiologic Measurements

The high-flow ATL group (73.4 ± 22.0 mm Hg, $P = .002$, Figure 2) had significantly improved arterial oxygenation measurements compared with those of the high-flow group (41.0 ± 11.7 mm Hg) after 30 minutes of reperfusion. Similarly, the controlled high-flow ATL group (123.6 ± 19.7 mm Hg, $P = .004$) had significantly improved arterial oxygenation measurements compared with those of the high-flow group (87.0 ± 27.5 mm Hg) after 30 minutes of reperfusion.

PAP was significantly lower in the high-flow ATL group (66.0 ± 7.4 mm Hg, $P = .015$, Figure 3) compared with that of the high-flow group (80.1 ± 12.3 mm Hg). Similarly, the controlled high-flow ATL (50.3 ± 6.4 mm Hg, $P = .003$) group had significantly lower PAP measurements compared with those of the controlled high-flow group (62.9 ± 7.8 mm Hg) after 30 minutes of reperfusion.

There was a trend toward decreased peak airway pressure in the high-flow ATL group (11.8 ± 0.45 mm Hg, $P = .086$) compared with that in the high-flow group (13.7 ± 0.57 mm Hg). There were no significant differences in peak airway pressure in the controlled high-flow ATL group

(18.5 ± 0.64 mm Hg, $P = .29$) compared with values in the controlled high-flow group (19.5 ± 0.68 mm Hg).

Lung Wet/Dry Weight Ratio

The wet/dry weight ratio was significantly lower in the high-flow ATL group (11.8 ± 1.28 , $P = .018$) compared with that in the high-flow group (13.7 ± 1.62). Wet/dry weight ratio was not significantly different between the controlled high-flow ATL group (6.0 ± 1.49 , $P = .184$) and the controlled high-flow group (6.9 ± 1.01).

Tissue Myeloperoxidase Assay

Myeloperoxidase activity was not significantly different between the high-flow (0.31 ± 0.09 Δ absorbance/mg dry weight/min) and high-flow ATL groups (0.29 ± 0.09 Δ absorbance/mg dry weight/min). Similarly, myeloperoxidase activity was not significantly different between the controlled high-flow (0.22 ± 0.08 Δ absorbance/mg dry weight/min) and controlled high-flow ATL (0.17 ± 0.06 Δ absorbance/mg dry weight/min) groups.

Discussion

Approximately 20% to 30% of all lung transplant recipients experience reperfusion injury, which has an associated mortality of 40% in some series.^{1,2} Although the exact mechanism of this process has not been fully discerned, clinical studies have suggested that certain patient populations, such as patients with preexisting pulmonary hypertension, might be at increased risk for reperfusion injury after lung trans-

plantation.⁷⁻⁹ In our own clinical practice, patients with preexisting pulmonary hypertension are at increased risk of reperfusion injury.⁶ A more severe reperfusion injury seems to occur in patients with preexisting pulmonary hypertension as well.⁷⁻⁹ This patient population would include patients with primary pulmonary hypertension in addition to patients with secondary pulmonary hypertension as a result of congenital heart defects. Additionally, however, patients undergoing lung transplantation for restrictive lung diseases often have severe pulmonary hypertension as a result of pulmonary fibrosis. Other authors, in addition to the present ones, have shown an increased risk of reperfusion injury in patients with restrictive lung disease.^{6,10}

One possible mechanism by which those patients have reperfusion injury is through mechanical disruption of the pulmonary vascular endothelium. This would result in increased pulmonary edema and lung dysfunction as a result of the disrupted endothelium. Another possible mechanism for the increased reperfusion injury seen in those patients is through increased hydrostatic gradient created by increased PAP, which might serve to drive fluid across endothelial membranes. Additionally, endothelial disruption results in collagen exposure, which might be serving to activate circulating leukocytes against the transplanted lung. Many studies have shown that circulating white blood cells are one of the major mediators of reperfusion injury after lung transplantation.¹¹⁻¹⁵

One of the major anti-inflammatory mechanisms used by endothelial cells is mediated through the release of adenosine.² Adenosine receptors are ubiquitous membrane receptors found on many inflammatory cell types, including macrophages and neutrophils.¹⁶⁻²⁰ Activation of these receptors results in suppression of the inflammatory function of these cells. Adenosine has been shown to be a protective agent in models of warm lung ischemia-reperfusion injury,²¹ cardiac ischemia-reperfusion injury,²² intestinal reperfusion injury,²³ and hepatic ischemia-reperfusion injury.²⁴ Different types of adenosine receptors exist (A_1 , A_{2A} , A_{2B} , and A_3) and have different functions. For example, the adenosine A_1 receptor can have proinflammatory effects, including neutrophil chemotaxis and neutrophil adherence to endothelial cells.²² To avoid these proinflammatory effects, we chose a selective A_{2A} receptor analogue. Adenosine receptor subclassification has shown specifically that activation of the adenosine A_{2A} receptor prevents leukocyte adhesion to endothelial cells, as well as inhibiting the release of toxic oxygen products.¹⁷

The present study demonstrates that leukocyte inhibition with ATL-146, which is a highly potent and specific activator of the adenosine A_{2A} receptor,²⁵ results in improved arterial oxygenation and PAP under both high-flow and controlled high-flow reperfusion conditions. Additionally, pulmonary edema, as assessed on the basis of wet/dry

weight ratio, was significantly lower in the high-flow ATL group compared with in the high-flow group. These data would suggest that the inflammatory cascade has a role in reperfusion injury after high-flow reperfusion.

Interestingly, although myeloperoxidase activity was lower in the high-flow ATL group compared with that in the high-flow group and in the controlled perfusion ATL group compared with that in the controlled perfusion group, these comparisons did not reach statistical significance. Had the experiment been carried out for a longer time period, the gradual buildup of sequestered leukocytes might have brought out more of a difference between the various groups. Another possibility, however, is that the adenosine analogue is acting on cells other than circulating leukocytes. Previously, we have shown that circulating leukocytes are not significantly involved in reperfusion injury until after 2 hours of reperfusion.¹⁵ Furthermore, our studies have also suggested that intrinsic pulmonary macrophages might be involved in the earliest phase of reperfusion injury after lung transplantation.²⁶ Alveolar macrophages, in addition to circulating neutrophils, are known to carry the A_{2A} receptor and thus might be the initial key target for the A_{2A} analogue. Another possibility is that the A_{2A} analogue was acting directly on the pulmonary vasculature, leading to vasodilation, although many studies have shown the action of this drug is on white blood cells.¹⁶⁻²⁰

One further observation in this study was the effect of controlled perfusion on reperfusion injury. Controlled perfusion seemed to improve physiologic measurements compared with high-flow reperfusion. Our group has previously published on this topic.²⁷

In summary, high-flow reperfusion can cause significant lung dysfunction after lung transplantation. Adenosine A_{2A} receptor activation with ATL-146 significantly reduces reperfusion injury associated with high-flow and controlled high-flow conditions, possibly by inhibiting white blood cells. Thus adenosine A_{2A} agonists might have a future clinical role in lung transplantation.

We thank Anthony Herring and Sheila Hammond for their expert technical advice and support.

References

1. Burdine J, Hertz MI, Snover DC, Bolman RM. Heart-lung and lung transplantation: perioperative pulmonary dysfunction. *Transplant Proc.* 1991;23:1176-7.
2. Novick RJ, Gehman KE, Ali IS, Lee J. Lung preservation: the importance of endothelial and alveolar type II cell integrity. *Ann Thorac Surg.* 1996;62:302-14.
3. McGregor CG, Daly RC, Peters SG, Midthun DE, Scott JP, Allen MS, et al. Evolving strategies in lung transplantation for emphysema. *Ann Thorac Surg.* 1994;57:1513-21.
4. Bando K, Paradis IL, Komatsu K, Konishi H, Matshushima M, Keena RJ, et al. Analysis of time-dependent risks for infection, rejection and death after pulmonary transplantation. *J Thorac Cardiovasc Surg.* 1995;109:49-59.

5. Breda MA, Hall TS, Stuart S, Baumgartner WA, Borkon AM, Brawn JD, et al. Twenty-four hour lung preservation by hypothermia and leukocyte depletion. *J Heart Transplant*. 1985;4:325-9.
6. King RC, Binns OAR, Rodriguz F, Kanithanon RC, Daniel TM, Spotnitz WD, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. *Ann Thorac Surg*. 2000;69:1681-5.
7. Aeba R, Griffith BP, Hardesty RL, Kormos RL, Armitage JM. Isolated lung transplantation for patients with Eisenmenger's syndrome. *Circulation*. 1993;88(suppl):452-5.
8. Bando K, Keenan RJ, Paradis IL, Konishi H, Komatsu K, Hardesty RL, et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. *Ann Thorac Surg*. 1994;58:1336-42.
9. Pasque MK, Kaiser LR, Dresler CM, Trulock E, Triantafillou AN, Cooper JC. Single lung transplantation for pulmonary hypertension. *J Thorac Cardiovasc Surg*. 1992;103:475-82.
10. Kramer MR, Marshall SE, McDougall MR, Kloneck A, Starnes VA, Lewiston NJ, et al. The distribution of ventilation and perfusion after single-lung transplantation in patients with pulmonary fibrosis and pulmonary hypertension. *Transplant Proc*. 1991;23(suppl):1215-6.
11. Eppinger MJ, Jones ML, Deeb GM, Bolling SF, Deeb GM. Pattern of injury and the role of neutrophils in reperfusion injury of the rat lung. *J Surg Res*. 1995;58:713-8.
12. Eppinger MJ, Deeb GM, Bolling SF, Ward PA. Mediators of ischemia reperfusion injury of rat lung. *Am J Pathol*. 1997;150:1773-84.
13. Schueler S, DeValeria PA, Hatanaka M, Cameron DE, Bando K, Zeebly M, et al. Successful twenty-four hour lung preservation with donor cooling and leukocyte depletion in an orthotopic double lung transplant model. *J Thorac Cardiovasc Surg*. 1992;104:73-82.
14. Uthoff K, Zehr KJ, Lee PC, Low RA, Baumgartner WA, Cameron DE, et al. Neutrophil modulation results in improved pulmonary function after 12 and 24 hours of preservation. *Ann Thorac Surg*. 1995;59:7-13.
15. Ross SD, Tribble CG, Gaughen JR Jr, Shockey KS, Parrino PE, Kron IL. Reduced neutrophil infiltration protects against lung reperfusion injury after transplantation. *Ann Thorac Surg*. 1999;67:1428-34.
16. Cronstein BN, Daguma L, Nichols D, Hutchinsosn AJ, Williams M. The adenosine/neutrophil paradox resolved: Human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. *J Clin Invest*. 1990;85:1150-7.
17. Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissman G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. *J Immunol*. 1992;148:1041-54.
18. Mullane K, Bullough D. Harnessing and endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. *J Mol Cell Cardiol*. 1995;27:1041-54.
19. Nolte D, Lorenzen A, Lehr H, Zimmer F, Klotz K, Messmer K. Reduction of posts ischemic leukocyte-endothelium interaction by adenosine via A2 receptor. *Naunyn Schmiedebergs Arch Pharmacol*. 1992;346:234-7.
20. Bullough DA, Magill MJ, Firestein GS, Mullane KM. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. *J Immunol*. 1995;155:2579-86.
21. Marts BC, Baudendistel LJ, Naunheim KS, Dahms TE. Protective effect of 2-chloroadenosine on lung ischemia-reperfusion injury. *J Surg Res*. 1993;54:523-9.
22. Lozza G, Conti A, Ongini E, Monopoli A. Cardioprotective effects of adenosine A1 and A2 receptor agonists in the isolated rat heart. *Pharmacol Res*. 1997;35:57-64.
23. Kaminski PM, Proctor KG. Attenuation of no-reflow phenomenon, neutrophil activation, and reperfusion injury in intestinal microcirculation by topical adenosine. *Circ Res*. 1989;65:426-35.
24. Todo S, Zhu Y, Zhang S, Jin MB, Ishizaki N, Tanaka H, et al. Attenuation of ischemic liver injury by augmentation of endogenous adenosine. *Transplantation*. 1997;63:217-23.
25. Sullivan GW, Linden J, Buster BL, Scheld WM. Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. *J Infect Dis*. 1999;180:1550-60.
26. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Kron IL. Pulmonary macrophages are involved reperfusion injury after lung transplantation. *Ann Thorac Surg*. 2001;71:1134-9.
27. Fiser SM, Kron IL, Cassada DC, Long SM, Kaza AK, Kern JA, Tribble CG. Controlled perfusion decreases lung transplant reperfusion injury in the setting of high flow reperfusion. *J Heart Lung Transplant*. 2002;21:687-91.

Discussion

Dr Ralph A. Schmid (Berne, Switzerland). Why did you use the Euro-Collins solution in these experiments? I think the era of Euro-Collins is over.

Dr Fiser. We still use Euro-Collins at our institution.

Dr Schmid. Did you look at reperfusion for longer times than 30 minutes? This is a very short observation time, and therefore the differences might not be significant.

Dr Fiser. No, we only looked at 30 minutes. I think our future studies involving high-flow reperfusion should be carried out for more extended time periods.